? Human cancer is comprised of a broad spectrum of phenotypes, based in part on the tissue of origin of the tumor. While cancer phenotypes are diverse, cancer biology has converged on shared pathways and molecular mechanisms of transformation among all tumor types. A multidisciplinary approach to defining promising molecular targets in selected pathways will utilize sophisticated mouse models in combination with bioinformatic integration of high throughput data from systems technology in order to drive discovery. ? ? Three established investigators Gilliland, Korsmeyer and Orkin, committed to mouse models of human cancer, are thematically aligned in this MMHCC proposal by the shared belief that interrogating mouse genetic models of cancer pathways will define unanticipated targets. Multiple shared interests are noted in each project at the intersections of tyrosine kinase, cell death, transcription and tumor suppressor pathways of oncogenesis. Existing or newly developed mouse models will be validated as accurate models of human cancer. The unique component of this application is to use genome wide techniques to further probe these models in order to identify resulting networks of genes and proteins that will provide new targets. Multiple high throughput assay systems will be developed within the context of the Center for Systems Biology (CSB) at DFCI. Marc Vidal, a leader in the emerging field of systems biology and a full participant of the applicant group, will enable transcriptome, proteome-interactome, and phenome profiles to create correlation maps, representing functional gene networks. The goal of this MMHCC proposal is to use these systems approaches to identify and then credential the most promising molecular targets within each cancer pathway. ? ? All investigators are committed to sharing resources and data with other members of the MMHCC and to the broader scientific community. ? ?

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRRB-U (J2))
Program Officer
Marks, Cheryl L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Dana-Farber Cancer Institute
United States
Zip Code
Hsu, Jessie Hao-Ru; Hubbell-Engler, Benjamin; Adelmant, Guillaume et al. (2017) PRMT1-Mediated Translation Regulation Is a Crucial Vulnerability of Cancer. Cancer Res 77:4613-4625
Xie, Huafeng; Peng, Cong; Huang, Jialiang et al. (2016) Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2. Cancer Discov 6:1237-1247
Zhu, Nan; Chen, Mo; Eng, Rowena et al. (2016) MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C. J Clin Invest 126:997-1011
Yin, Jie; Leavenworth, Jianmei W; Li, Yang et al. (2015) Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity. Proc Natl Acad Sci U S A 112:15988-93
Helming, Katherine C; Wang, Xiaofeng; Roberts, Charles W M (2014) Vulnerabilities of mutant SWI/SNF complexes in cancer. Cancer Cell 26:309-317
Kim, Kimberly H; Roberts, Charles W M (2014) Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. Cancer Genet 207:365-72
Perry, Jennifer A; Kiezun, Adam; Tonzi, Peter et al. (2014) Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A 111:E5564-73
Deshpande, Aniruddha J; Deshpande, Anagha; Sinha, Amit U et al. (2014) AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. Cancer Cell 26:896-908
Wang, Xiaofeng; Roberts, Charles W M (2014) CARMA: CARM1 methylation of SWI/SNF in breast cancer. Cancer Cell 25:3-4
Helming, Katherine C; Wang, Xiaofeng; Wilson, Boris G et al. (2014) ARID1B is a specific vulnerability in ARID1A-mutant cancers. Nat Med 20:251-4

Showing the most recent 10 out of 42 publications